Total costs of chimeric antigen receptor T-cell immunotherapy
Menée dans un contexte américain, cette étude analyse les coûts associés à l'utilisation des immunothérapies à base de lymphocytes T à récepteur antigénique chimérique
In 2017, the US Food and Drug Administration approved the drugs tisagenlecleucel (Kymriah; Novartis) and axicabtagene ciloleucel (Yescarta; Kite Pharma) as the first chimeric antigen receptor T-cell (CAR-T) immunotherapies. Treatment with tisagenlecleucel has been priced at $475 000 and axicabtagene ciloleucel at $373 000; however, these prices are for the drug products alone and do not account for the costs associated with leukapheresis, lymphodepletion therapy, and the adverse effects of CAR-T immunotherapy. These costs are not negligible as 43 patients (44%) who received tisagenlecleucel in clinical trials required stays in the intensive care unit for cytokine release syndrome (CRS).1 In this study, we estimated the total costs of CAR-T immunotherapy, including nondrug costs, using publicly available data.
JAMA Oncology 2018